Vol. 21/No. 5

While cybersecurity upgrades may require additional software and hardware and come at an expense, experts said the expenses are worth it, as they help avoid government fines for data breaches, data recovery costs, and the potential for loss of public trust.

Investigators have turned their attention to B-cell maturation antigen, which offers an ideal target for multiple myeloma therapy because of its restricted expression pattern.

Investigators propose that a PI3K-δ,γ inhibitor currently indicated for the treatment of 3 hematologic malignancies may be a key to boosting response rates in peripheral T-cell lymphoma, a disease setting defined by poor prognoses.

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

Dana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.

Adam D. Cohen, MD, discusses the prospects for BCMA-targeting options in multiple myeloma.

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Patients with preexisting inflammatory bowel disease have a significantly higher risk of developing gastrointestinal adverse events during treatment with an immunotherapybased anticancer regimen than those without inflammatory bowel disease.

During a recent OncLive Peer Exchange®, a panel of experts sought to answer several key questions regarding the management of advanced, hormone receptor–positive breast cancer, particularly with CDK4/6 inhibitors.

Clinical trials in oncology serve several purposes; these efforts ultimately help define and, potentially, modify the "standard of care" in routine cancer management.